Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas W Mapel

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Respiratory Medicine|September 6, 2005
Predicting the costs of managing patients with chronic obstructive pulmonary diseaseDouglas W Mapel, Garnett P McMillan, Floyd J Frost, et al.
COPD|August 2, 2008
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early interventionMarc Decramer, Stephen Rennard, Thierry Troosters, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 20, 2024
Disease Burden and Health-Related Quality of Life (HRQoL) of Chronic Obstructive Pulmonary Disease (COPD) in the US - Evidence from the Medical Expenditure Panel Survey (MEPS) from 2016-2019Melissa H Roberts, David M Mannino, Douglas W Mapel, et al.
Chest|March 15, 2008
Burden of concomitant asthma and COPD in a Medicaid populationFadia T Shaya, Du Dongyi, Manabu O Akazawa, et al.
Respiratory Medicine|November 18, 2005
Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organizationYves M Gagnon, Adrian R Levy, Michael D Spencer, et al.
Chest|December 2, 2023
National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029David M Mannino, Melissa H Roberts, Douglas W Mapel, et al.
The American Journal of Managed Care|February 21, 2018
Claims-based risk model for first severe COPD exacerbationRichard H Stanford, Arpita Nag, Douglas W Mapel, et al.
Annals of the American Thoracic Society|April 13, 2016
Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims DataRichard H Stanford, Arpita Nag, Douglas W Mapel, et al.
The American Journal of Geriatric Pharmacotherapy|February 22, 2011
Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary diseaseBruce C Stuart, Linda Simoni-Wastila, Ilene H Zuckerman, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Respiratory Medicine|November 18, 2008
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPDStephanie R Earnshaw, Michele R Wilson, Anand A Dalal, et al.
Respiratory Medicine|September 6, 2005
Predicting the costs of managing patients with chronic obstructive pulmonary diseaseDouglas W Mapel, Garnett P McMillan, Floyd J Frost, et al.
COPD|August 2, 2008
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early interventionMarc Decramer, Stephen Rennard, Thierry Troosters, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 20, 2024
Disease Burden and Health-Related Quality of Life (HRQoL) of Chronic Obstructive Pulmonary Disease (COPD) in the US - Evidence from the Medical Expenditure Panel Survey (MEPS) from 2016-2019Melissa H Roberts, David M Mannino, Douglas W Mapel, et al.
Chest|March 15, 2008
Burden of concomitant asthma and COPD in a Medicaid populationFadia T Shaya, Du Dongyi, Manabu O Akazawa, et al.
Respiratory Medicine|November 18, 2005
Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organizationYves M Gagnon, Adrian R Levy, Michael D Spencer, et al.
Chest|December 2, 2023
National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029David M Mannino, Melissa H Roberts, Douglas W Mapel, et al.
The American Journal of Managed Care|February 21, 2018
Claims-based risk model for first severe COPD exacerbationRichard H Stanford, Arpita Nag, Douglas W Mapel, et al.
Annals of the American Thoracic Society|April 13, 2016
Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims DataRichard H Stanford, Arpita Nag, Douglas W Mapel, et al.
The American Journal of Geriatric Pharmacotherapy|February 22, 2011
Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary diseaseBruce C Stuart, Linda Simoni-Wastila, Ilene H Zuckerman, et al.
Pageof 6